BioSpace News Archive

NeuroTherapia, an early-stage clinical pharmaceutical company, announced that it has received a grant from the Alzheimer’s Association Part the Cloud program for the development of its first-in-class drug, NTRX-07, for the treatment of Alzheimer’s disease.

Karyopharm Therapeutics Inc. announced that it has entered into a series of financing transactions that will extend the Company’s debt maturities into 2028 and 2029, well beyond the Company’s planned Phase 3 data readouts in 2025.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, reported financial results for the quarter ended March 31, 2024, and highlighted select corporate milestones and progress on its key clinical development programs.

Treos Bio, a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, said investigators will present new results from a phase 2 trial of the company’s lead product candidate PolyPEPI1018 in combination with Roche’s PD-L1 inhibitor atezolizumab in patients with late-stage microsatellite stable metastatic colorectal cancer at the 2024 ASCO Annual Meeting.

Vericel Corporation reported financial results and business highlights for the first quarter ended March 31, 2024.

BioAtla, Inc. announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the Citizens JMP Life Sciences Conference, to be held in New York, NY May 13-14, 2024.

Jnana Therapeutics announced that Joanne Kotz, Ph.D., Co-founder and Chief Executive Officer, will present a corporate overview at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024 at 2:05 p.m. ET.

Keros Therapeutics, Inc. provided a business update and reported financial results for the quarter ended March 31, 2024.

Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, announced that it will participate in two upcoming investor conferences.

Fulcrum Therapeutics, Inc. today announced the publication of results from its Phase 2b clinical trial of losmapimod for the treatment of facioscapulopumeral muscular dystrophy (FSHD).